10-Q: Altimmune Reports First Quarter 2025 Financial Results and Provides Business Update

Altimmune, a late clinical-stage biopharmaceutical company, announces its financial results for the first quarter of 2025 and provides an update on its business operations, including progress on its lead program, pemvidutide, and expansion into new indications.

Summary

• Altimmune, Inc. reported a net loss of $19.575 million, or $0.26 per share, for the three months ended March 31, 2025, compared to a net loss of $24.394 million, or $0.34 per share, for the same period in 2024.
• The company's cash, cash equivalents, restricted cash, and short-term investments totaled $149.9 million as of March 31, 2025.
• Research and development expenses decreased by $5.7 million, or 26%, compared to the same period in 2024, primarily due to reduced expenses related to the pemvidutide program.
• General and administrative expenses increased by $0.7 million, or 13%, compared to the same period in 2024, mainly due to increased stock compensation and professional fees.
• The company is pursuing two additional indications for pemvidutide: Alcohol Use Disorder (AUD) and Alcohol-Associated Liver Disease (ALD).
• A Phase 2 AUD trial is expected to begin in the second quarter of 2025, and a Phase 2 ALD trial is expected to begin in the third quarter of 2025.
• In April 2025, Altimmune raised $16.3 million in net proceeds through the issuance of 3,278,902 shares of common stock.
• On May 13, 2025, the company entered into a Loan and Security Agreement with Hercules Capital, Inc. for up to $100.0 million in term loans.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, the decrease in net loss and the expansion into new indications are positive developments. The secured loan provides additional financial stability.

Positives

• The net loss decreased compared to the same period in the previous year.
• The company has a strong cash position with $149.9 million in cash, cash equivalents, and short-term investments.
• The expansion of pemvidutide into new indications (AUD and ALD) represents a potential growth opportunity.
• Securing a loan agreement with Hercules Capital, Inc. provides additional financial flexibility.
• The company recorded a discrete tax benefit of approximately $0.7 million related to a portion of carryback claims with the State of Maryland.

Negatives

• The company continues to operate at a loss, with a net loss of $19.575 million for the quarter.
• Research and development expenses decreased, which could potentially slow down the progress of existing programs if not managed carefully.
• The company has an accumulated deficit of $581.0 million as of March 31, 2025.

Risks

• The company has not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales.
• The company has incurred significant losses since it commenced operations.
• The company may require additional capital beyond its currently anticipated amounts.
• The company is subject to various covenants related to its term loan obligation, which could restrict its operating activities.
• The company is subject to risks related to economic uncertainty, capital market disruption, and ongoing military conflicts and geopolitical instability.
• The company is subject to risks related to disruptions at the FDA, the SEC and other government agencies or comparable regulatory authorities caused by funding shortages or global health concerns.

Future Outlook

The company expects to begin a Phase 2 AUD trial for pemvidutide in the second quarter of 2025 and a Phase 2 ALD trial in the third quarter of 2025. The company believes its cash on hand, together with expected cash receipts from R&D incentives, are sufficient to fund operations for at least a twelve-month period from the issuance date of the financial statements.

Industry Context

Altimmune is operating in the competitive biopharmaceutical industry, focusing on liver and cardiometabolic diseases. The company's focus on pemvidutide, a GLP-1/glucagon dual receptor agonist, aligns with the growing interest in these types of therapies for MASH, obesity, and related conditions. The expansion into AUD and ALD reflects a strategic effort to leverage the potential of pemvidutide in addressing unmet medical needs.

Comparison to Industry Standards

• It is difficult to compare Altimmune's results directly to industry standards without knowing the specific stage of development and focus of comparable companies.
• However, the company's cash position of $149.9 million provides a runway for continued clinical development.
• The net loss of $19.575 million is typical for a clinical-stage biopharmaceutical company with no products on the market.
• Comparable companies in the biopharmaceutical industry include Madrigal Pharmaceuticals, Viking Therapeutics, and Intercept Pharmaceuticals, which are also focused on developing therapies for liver diseases.
• These companies are often compared based on the progress of their clinical trials, the potential market size for their therapies, and their financial resources.

Legal Proceedings

• A shareholder derivative complaint filed on June 4, 2024, was dismissed without prejudice on February 3, 2025.

Stakeholder Impact

• Shareholders: The financial results and business updates provide information for investment decisions.
• Employees: The company's financial stability and progress on clinical programs impact job security and potential for growth.
• Customers: The development of new therapies for liver and cardiometabolic diseases could provide new treatment options.
• Creditors: The company's ability to repay its debts is dependent on its financial performance and access to capital.

Next Steps

• Begin Phase 2 AUD trial for pemvidutide in the second quarter of 2025.
• Begin Phase 2 ALD trial for pemvidutide in the third quarter of 2025.
• Continue to pursue additional equity or debt financing and monetization of existing programs.

Key Dates

Keywords

Altimmune, pemvidutide, financial results, biopharmaceutical, clinical trials, MASH, ALD, AUD, loan agreement, Hercules Capital, stock offering, net loss, research and development, capital resources